Ordering
Available Variants1 mL
CHA.17923-1mL
Price
€180.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 mL | CHA.17923-1mL | €180.00 |
≥98% (HPLC), solution, Estrogen receptor antagonist
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H29NO2 |
|---|---|
| CAS Number | 68392-35-8 |
| Molecular Weight | 387.51 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| Form | solution |
| Quality level | 200 |
Safety Information Handling visibility
| pictograms |
GHS02
GHS08
GHS07
   GHS02,GHS08,GHS07
|
|---|---|
| signalword | Danger |
| hcodes | H225,H319,H350,H360FD,H412 |
| pcodes | P202 - P210 - P233 - P273 - P305 + P351 + P338 - P308 + P313 |
| Hazard Classifications | Aquatic Chronic 3 - Carc. 1B - Eye Irrit. 2 - Flam. Liq. 2 - Repr. 1B |
| Storage Class | 3 - Flammable liquids |
| wgk | WGK 3 |
| flash_point_f | 55.4 °F |
| flash_point_c | 13 °C |
Technical Overview & Applications Use-case context
4-Hydroxytamoxifen, also known as afimoxifene, is a non-steroidal anti-estrogenic compound with the CAS number 68392-35-8. It is a primary metabolite of tamoxifen, a widely used selective estrogen receptor modulator. 4-Hydroxytamoxifen has been shown to exhibit potent anti-estrogenic activity, binding to estrogen receptors and inhibiting the growth of estrogen-dependent tumors. Its mechanism of action involves competition with estrogen for binding to the estrogen receptor, thereby blocking the proliferative effects of estrogen on cancer cells. As a result, 4-hydroxytamoxifen has been investigated for its potential therapeutic applications in the treatment of hormone-dependent cancers, such as breast cancer. Further research is ongoing to fully elucidate the pharmacological properties and clinical potential of this compound. Its chemical structure and biological activity make it an important area of study in the field of oncology and endocrinology.
